Memphasys Limited (ASX: MEM) Investor Webinar

Memphasys Limited (ASX: MEM) is pleased to invite investors to this webinar, the webinar will feature a presentation from Memphasys Managing Director and CEO Dr David Ali providing an update on the Company’s Felix^TM System clinical trial progress which has reached 90% completion. The presentation will also detail Memphasys’ fast-tracked regulatory strategy which will see the Company target CE mark registration in Europe post-trial completion, offering a faster and more lucrative pathway than the Australian Therapeutic Goods Administration (TGA) registration.

Memphasys has also commenced a 3-year equine study which is anticipated to produce commercial outcomes within 12 months.

Following the formal presentation, investors have the opportunity to submit questions directly to management during a moderated Q&A session.

Time:   11am AEDT / 8am AWST

Date:    25^th October 2024